Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。
ターゲット

Microtubule (human endothelial cells)

IC50

0.1 pM [1]

In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXDTWM2OD1yLkCwNFI5PyEQvF2= Ml;oV2FPT0WU
LC-2-ad M3\MPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\sXIlsUUN3ME2wMlAxODNzNzFOwG0> NGToeJpUSU6JRWK=
RL95-2 M2m5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\nXWlEPTB;MD6wNFA3PjhizszN M17zS3NCVkeHUh?=
MZ1-PC MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\LWYJOUUN3ME2wMlAxODd{OTFOwG0> NI\SS4ZUSU6JRWK=
TE-8 M4rr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHaVWtKSzVyPUCuNFAyOTdizszN M4iwN3NCVkeHUh?=
SW954 NWjmO4NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHrNodKSzVyPUCuNFAyOTlizszN MmjSV2FPT0WU
TE-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMECxNlMh|ryP M{fVTXNCVkeHUh?=
PSN1 NUG0XldYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXyZWUzUUN3ME2wMlAxOTNizszN NFLFeYhUSU6JRWK=
MOLT-4 NWnhUYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfBfXVYUUN3ME2wMlAxOTR7IN88US=> M4LXW3NCVkeHUh?=
697 NX;aS5ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31V4NUUUN3ME2wMlAxOTVizszN MXfTRW5ITVJ?
ETK-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjV5lKSzVyPUCuNFAyPTJizszN MVjTRW5ITVJ?
TE-10 MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMECxOVQh|ryP NXvK[4EyW0GQR1XS
HUTU-80 NInMcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X4UWlEPTB;MD6wNFE3QCEQvF2= NGXzN5NUSU6JRWK=
NTERA-S-cl-D1 M3fyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrSU5ZKSzVyPUCuNFAzODlizszN NXXjZVh6W0GQR1XS
MFH-ino NGqwXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2raNGlEPTB;MD6wNFI3QCEQvF2= M3PtZnNCVkeHUh?=
IA-LM M3rpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13sZ2lEPTB;MD6wNFI5KM7:TR?= NWTwPGx3W0GQR1XS
MC116 NH\SWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLuTWM2OD1yLkCwNlg6KM7:TR?= MWDTRW5ITVJ?
RKO MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUntNnlRUUN3ME2wMlAxOjl6IN88US=> NYW1eWFwW0GQR1XS
MRK-nu-1 NV7iWXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzBUINKSzVyPUCuNFAzQTlizszN NY[zZppjW0GQR1XS
VA-ES-BJ MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP6ZldKSzVyPUCuNFA{KM7:TR?= MWHTRW5ITVJ?
KALS-1 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jhXGlEPTB;MD6wNFMxQCEQvF2= MorrV2FPT0WU
BB30-HNC NXPpZVhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnruTWM2OD1yLkCwN|E1KM7:TR?= NIrqOGlUSU6JRWK=
ACN M{DpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD1yLkCwN|E3KM7:TR?= M4nKOnNCVkeHUh?=
TE-9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnVTWM2OD1yLkCwN|I3KM7:TR?= M2Pn[nNCVkeHUh?=
SIG-M5 M2fa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzMeJFKSzVyPUCuNFA{OjdizszN NFHueZRUSU6JRWK=
no-10 M17zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tUWlEPTB;MD6wNFM3OiEQvF2= NY\qNIx3W0GQR1XS
EW-1 NYfud4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7rXGlKSzVyPUCuNFA{PzFizszN NWfqNHhSW0GQR1XS
SK-LMS-1 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXLPGg{UUN3ME2wMlAxPDBzIN88US=> NGXCd|NUSU6JRWK=
GT3TKB MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfjUHl1UUN3ME2wMlAxPDN2IN88US=> MnvkV2FPT0WU
ES4 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS2TWM2OD1yLkCwOFQ6KM7:TR?= MY\TRW5ITVJ?
IMR-5 M4[wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\MTWM2OD1yLkCwOFUh|ryP M2exXHNCVkeHUh?=
NCI-H1648 NI\ofJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEC0Olkh|ryP NGj3R25USU6JRWK=
MV-4-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dz[2lEPTB;MD6wNFQ4PSEQvF2= NUfnbJROW0GQR1XS
SK-UT-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XtV2lEPTB;MD6wNFQ5KM7:TR?= M3rPV3NCVkeHUh?=
NB13 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\yZZNKSzVyPUCuNFA1QTFizszN M2mz[HNCVkeHUh?=
DJM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jVeWlEPTB;MD6wNFU{KM7:TR?= Ml36V2FPT0WU
ES8 NHnBdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTEeItKSzVyPUCuNFA2OzhizszN MWnTRW5ITVJ?
TE-6 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\PZmlEPTB;MD6wNFU4KM7:TR?= MYXTRW5ITVJ?
KS-1 M{LCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKVYpKSzVyPUCuNFA2QDJizszN NX;PT21rW0GQR1XS
TE-1 M2rTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmTWVSUUN3ME2wMlAxPjB4IN88US=> MoDMV2FPT0WU
ATN-1 NG[yUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjobZRPUUN3ME2wMlAxPjB7IN88US=> M3exdnNCVkeHUh?=
A4-Fuk NHfUeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonITWM2OD1yLkCwOlEyKM7:TR?= MkHrV2FPT0WU
ALL-PO NEPoZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEC2N{DPxE1? MmK3V2FPT0WU
BE-13 NG[2SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEC2N|Yh|ryP M3zuRXNCVkeHUh?=
KM12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP4OYVKSzVyPUCuNFA3OzdizszN NGPlc3dUSU6JRWK=
NOS-1 NEP5RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW1TWM2OD1yLkCwOlUh|ryP NHfp[VFUSU6JRWK=
SW962 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG2TWM2OD1yLkCwOlYzKM7:TR?= M{fkUXNCVkeHUh?=
OCUB-M MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;aTWM2OD1yLkCwOlYzKM7:TR?= Mlz0V2FPT0WU
NCI-H510A MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHaR2RKSzVyPUCuNFA3PjVizszN MnzLV2FPT0WU
EW-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmwZZhnUUN3ME2wMlAxPjl2IN88US=> NVOx[Wl{W0GQR1XS
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPWSGoxUUN3ME2wMlAxPzF{IN88US=> MkHQV2FPT0WU
LS-411N NVH6cYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnqfm1xUUN3ME2wMlAxPzF5IN88US=> Ml\OV2FPT0WU
Becker NEXXU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3NTWM2OD1yLkCwO|Ih|ryP MV;TRW5ITVJ?
HC-1 NX\pWYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn6V|VKSzVyPUCuNFA4OjFizszN M1i3XXNCVkeHUh?=
CESS M2DTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOyXodKSzVyPUCuNFA4OzdizszN MW\TRW5ITVJ?
KURAMOCHI NYLyXXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[3OWlEPTB;MD6wNFc1QCEQvF2= Mm\oV2FPT0WU
TGBC24TKB NFKzNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEC3OVIh|ryP MlLRV2FPT0WU
SW982 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPkflNKSzVyPUCuNFA4PjZizszN NGTPNpJUSU6JRWK=
HCE-4 M{jTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrkW5RKSzVyPUCuNFA4PjdizszN NV32OYVVW0GQR1XS
LOUCY NVPRWoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TnemlEPTB;MD6wNFc4PSEQvF2= NF\kfoRUSU6JRWK=
8-MG-BA NHvuZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEC3PVYh|ryP MkfUV2FPT0WU
HT-144 NYP0fpJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\hW2tKSzVyPUCuNFA5KM7:TR?= M{DycXNCVkeHUh?=
LXF-289 NYXKbWc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LkdGlEPTB;MD6wNFgyQCEQvF2= M2f6cHNCVkeHUh?=
RS4-11 NV[3R2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj4XmxzUUN3ME2wMlAxQDN4IN88US=> NXTpRYRkW0GQR1XS
DEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\Q[GlEPTB;MD6wNFg1PSEQvF2= M3GwXXNCVkeHUh?=
OCI-AML2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEC4OVIh|ryP M3HacnNCVkeHUh?=
CCRF-CEM MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi1TWM2OD1yLkCwPFcyKM7:TR?= MkHKV2FPT0WU
A388 NEDwXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC1SWtKSzVyPUCuNFA5PzRizszN NV\wfYt{W0GQR1XS
KNS-42 NHHRfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPGbopzUUN3ME2wMlAxQDlzIN88US=> NHrpd25USU6JRWK=
OVCAR-4 NHS4W|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoexTWM2OD1yLkCwPVA1KM7:TR?= MoXyV2FPT0WU
NCI-H1355 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuVHN4UUN3ME2wMlAxQTF2IN88US=> M2G3UXNCVkeHUh?=
BL-70 NFHQOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnhOmVKSzVyPUCuNFA6OyEQvF2= NVeyN4J5W0GQR1XS
BL-41 NUXGfmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTpTWM2OD1yLkCwPVM1KM7:TR?= MYTTRW5ITVJ?
A101D MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;3U2NKSzVyPUCuNFA6PiEQvF2= NEDKNJlUSU6JRWK=
HL-60 M2DybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fX[GlEPTB;MD6wNFk3PiEQvF2= M1n0SHNCVkeHUh?=
COR-L279 NFvJOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfUZ3FKSzVyPUCuNFA6QTlizszN MUjTRW5ITVJ?
NCI-SNU-16 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETkXYlKSzVyPUCuNFExODhizszN MXzTRW5ITVJ?
Calu-6 M33adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEGwNVIh|ryP MYTTRW5ITVJ?
SR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEGwNlYh|ryP NFrTO5lUSU6JRWK=
QIMR-WIL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq1W4tZUUN3ME2wMlAyODN|IN88US=> NYToUY9pW0GQR1XS
LB647-SCLC NEj1SVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXKPW9KSzVyPUCuNFExPTFizszN M{jhXXNCVkeHUh?=
RPMI-8226 NFixbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\uTWM2OD1yLkCxNVAzKM7:TR?= NVPFW|dmW0GQR1XS
SK-PN-DW Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEGxNVIh|ryP NX64dHFPW0GQR1XS
SF268 NInsOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nt[GlEPTB;MD6wNVE2OSEQvF2= NGSzdYlUSU6JRWK=
HD-MY-Z NGLaSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP4TWM2OD1yLkCxNVY{KM7:TR?= NEPpOFVUSU6JRWK=
DOHH-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEGyNFMh|ryP M{jjenNCVkeHUh?=
SCC-3 NGq4[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEGyNFQh|ryP MV3TRW5ITVJ?
ST486 M1vhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDBTWM2OD1yLkCxNlA1KM7:TR?= MmfGV2FPT0WU
NALM-6 NYPzPZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD1yLkCxNlE1KM7:TR?= NXz0[phXW0GQR1XS
NCI-H1436 M{X4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGxTWM2OD1yLkCxNlMyKM7:TR?= NXWyUpBMW0GQR1XS
KE-37 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj2ZpZKSzVyPUCuNFEzOzRizszN M3jVPHNCVkeHUh?=
RPMI-8402 NVvRSZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT2TWM2OD1yLkCxNlU3KM7:TR?= M{PWWXNCVkeHUh?=
RXF393 NIfWZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXHTWM2OD1yLkCxNlU4KM7:TR?= MnjWV2FPT0WU
KARPAS-45 NYi2RW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfRdmZYUUN3ME2wMlAyOjdizszN NELwRXRUSU6JRWK=
HOP-62 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjnSGhMUUN3ME2wMlAyOjd4IN88US=> NH;HUYFUSU6JRWK=
ES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vZemlEPTB;MD6wNVI5QCEQvF2= MVrTRW5ITVJ?
L-363 NVLUUHpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTsUXFKSzVyPUCuNFE{PTFizszN NHvMeZpUSU6JRWK=
GI-1 NXzmU5V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\oWlJiUUN3ME2wMlAyOzd|IN88US=> MYrTRW5ITVJ?
CTV-1 M3LXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3v[JJKSzVyPUCuNFE1PzhizszN NHfFXWZUSU6JRWK=
TE-5 NYDDXIE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fK[WlEPTB;MD6wNVQ6PiEQvF2= NIq4dohUSU6JRWK=
SNU-C2B NXmwRZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYXWlEPTB;MD6wNVQ6PiEQvF2= M1zrc3NCVkeHUh?=
K-562 NW\6VZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFTWM2OD1yLkCxOVE3KM7:TR?= NXHwfFBNW0GQR1XS
SNB75 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrRTWM2OD1yLkCxOVQh|ryP NXLtfYlJW0GQR1XS
MOLT-13 NIHFOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD1yLkCxOlM4KM7:TR?= MlrYV2FPT0WU
LS-123 NITpSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:0TWM2OD1yLkCxOlY1KM7:TR?= M1nZenNCVkeHUh?=
NCI-SNU-5 NHrJTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O4N2lEPTB;MD6wNVcxOSEQvF2= Mnv3V2FPT0WU
Daudi NFXS[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTPTWM2OD1yLkCxO|A5KM7:TR?= MlPZV2FPT0WU
A253 NVPaOYxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPTTI5{UUN3ME2wMlAyPzN6IN88US=> M4XZeHNCVkeHUh?=
TGBC1TKB M2K4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInDNW9KSzVyPUCuNFE4PTJizszN MnT6V2FPT0WU
SJSA-1 M1TZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfoTWM2OD1yLkCxO|Y4KM7:TR?= NF7oNGJUSU6JRWK=
NCCIT MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLWTWM2OD1yLkCxO|Y6KM7:TR?= MXTTRW5ITVJ?
NCI-H69 NV\nfpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf1TmZKSzVyPUCuNFE4PzhizszN MWHTRW5ITVJ?
SH-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHScpdKSzVyPUCuNFE5QTVizszN NEPYUY5USU6JRWK=
HCC1187 NHH6cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17kZWlEPTB;MD6wNVkzPCEQvF2= M4fNbnNCVkeHUh?=
HCC1599 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XBXWlEPTB;MD6wNlAzKM7:TR?= MonLV2FPT0WU
ONS-76 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPYZVZqUUN3ME2wMlAzODN4IN88US=> NFXFVYdUSU6JRWK=
KU812 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1SmlEPTB;MD6wNlA{QSEQvF2= NET1UHVUSU6JRWK=
ML-2 NUT4eoZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr3[olXUUN3ME2wMlAzODR5IN88US=> NYrBVnpYW0GQR1XS
HCE-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEKwPVIh|ryP NFHYOYJUSU6JRWK=
NCI-H446 NXj1TohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEKxNVIh|ryP MWrTRW5ITVJ?
RPMI-6666 NFv3[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi1ZnFKSzVyPUCuNFIyPDlizszN NE\SfVFUSU6JRWK=
MOLT-16 M4HMPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnoNJo5UUN3ME2wMlAzOTV|IN88US=> MWTTRW5ITVJ?
JiyoyeP-2003 M{DieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD1yLkCyNVc3KM7:TR?= MUfTRW5ITVJ?
MHH-PREB-1 NGfWUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEKxPVEh|ryP NYeycnRpW0GQR1XS
MC-CAR NVrIOnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPlWGZKSzVyPUCuNFI{OjZizszN NF3WRVlUSU6JRWK=
BC-3 NHe1WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLWNmRKSzVyPUCuNFI{PDRizszN M4CxbHNCVkeHUh?=
KINGS-1 M4fOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfwTWM2OD1yLkCyN|U2KM7:TR?= NVy2T4k1W0GQR1XS
PF-382 M{DS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEKzO|gh|ryP NYm0bmVbW0GQR1XS
J-RT3-T3-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHJZ5BwUUN3ME2wMlAzOzh|IN88US=> NF\acnNUSU6JRWK=
SF539 NWnpOXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknlTWM2OD1yLkCyOFAyKM7:TR?= NWHOWlQ{W0GQR1XS
LB831-BLC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1yLkCyOFg2KM7:TR?= NFH2c4ZUSU6JRWK=
DMS-114 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHCTWM2OD1yLkCyOVAzKM7:TR?= NYjEelRPW0GQR1XS
LB1047-RCC MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLTTWM2OD1yLkCyOVEh|ryP MoHGV2FPT0WU
LB771-HNC NEHzcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[1SWxvUUN3ME2wMlAzPTN2IN88US=> MV;TRW5ITVJ?
BB65-RCC NFPEXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;wTWM2OD1yLkCyOVM1KM7:TR?= M2PnOnNCVkeHUh?=
BV-173 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEK1OVQh|ryP MYDTRW5ITVJ?
ARH-77 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\4fmlEPTB;MD6wNlYxOSEQvF2= NYS1fGRbW0GQR1XS
IST-MEL1 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\xTWM2OD1yLkCyOlI{KM7:TR?= Mn6yV2FPT0WU
NB1 NGjmV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ziPWlEPTB;MD6wNlY5PyEQvF2= M4i2cnNCVkeHUh?=
EoL-1-cell M4fqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nKfGlEPTB;MD6wNlY5QCEQvF2= MlraV2FPT0WU
KY821 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnKTWM2OD1yLkCyOlk4KM7:TR?= MXHTRW5ITVJ?
CMK NWDrN2R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmyc4F{UUN3ME2wMlAzPzN2IN88US=> MVLTRW5ITVJ?
NCI-H2126 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XGR2lEPTB;MD6wNlc3QCEQvF2= NGXEXVZUSU6JRWK=
NCI-H526 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEK4PVEh|ryP MlfOV2FPT0WU
COLO-684 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEK5NFgh|ryP NVqyRVdQW0GQR1XS
NCI-H747 NIXWUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;V[GlEPTB;MD6wNlk{OyEQvF2= M4XuR3NCVkeHUh?=
JAR MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEK5OFYh|ryP NYTpXGw6W0GQR1XS
MEG-01 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zSW2lEPTB;MD6wNlk4QCEQvF2= MnXPV2FPT0WU
MONO-MAC-6 M2jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUeySXNTUUN3ME2wMlA{ODJ|IN88US=> NUP6SJZDW0GQR1XS
IST-SL1 NFnxdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWToZYlVUUN3ME2wMlA{ODR{IN88US=> NFjOPJZUSU6JRWK=
CPC-N MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm5PI9xUUN3ME2wMlA{ODd7IN88US=> M2nabnNCVkeHUh?=
NCI-H1963 NIPuXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEOxN|Eh|ryP M2\4RnNCVkeHUh?=
K052 NHXQcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm4dWlyUUN3ME2wMlA{OjR5IN88US=> M3jBN3NCVkeHUh?=
KM-H2 NH[1emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\WW2ZKSzVyPUCuNFM{ODdizszN M3nG[HNCVkeHUh?=
TE-12 M1rFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEOzNFkh|ryP M3n3UnNCVkeHUh?=
TK10 M33SVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEOzOVYh|ryP NUPRN5RZW0GQR1XS
NMC-G1 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni4TWM2OD1yLkCzOFUzKM7:TR?= M1HGXHNCVkeHUh?=
no-11 NX7sXmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP2RoJPUUN3ME2wMlA{PDd6IN88US=> MoX3V2FPT0WU
NCI-H524 M4D4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7RTWM2OD1yLkCzOVI6KM7:TR?= MWfTRW5ITVJ?
MHH-CALL-2 NXLwWJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTqTWM2OD1yLkCzOVYzKM7:TR?= MmjhV2FPT0WU
GB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnqcWFzUUN3ME2wMlA{PiEQvF2= NEnyVYVUSU6JRWK=
OPM-2 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDUTWM2OD1yLkCzOlc{KM7:TR?= NGjmWY1USU6JRWK=
RH-1 M{XO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Kwc2lEPTB;MD6wN|gyQSEQvF2= MlO4V2FPT0WU
NCI-H64 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CyUmlEPTB;MD6wN|g2PyEQvF2= M2rS[HNCVkeHUh?=
EVSA-T M3fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\BTWM2OD1yLkCzPVI{KM7:TR?= Mo\xV2FPT0WU
KARPAS-299 M2[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEO5PEDPxE1? MmC5V2FPT0WU
MZ7-mel NWnGcZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMESwOEDPxE1? Mo[yV2FPT0WU
LB373-MEL-D M3XkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjUNWJKSzVyPUCuNFQyODVizszN NGjybYJUSU6JRWK=
HEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHOS|dKSzVyPUCuNFQyPCEQvF2= NUixOHVGW0GQR1XS
SW872 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfPO2hKSzVyPUCuNFQzOSEQvF2= MY\TRW5ITVJ?
DU-4475 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTMSXdZUUN3ME2wMlA1OjR2IN88US=> Ml7EV2FPT0WU
IST-SL2 M3r6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX33UmI5UUN3ME2wMlA1Ojd3IN88US=> MX\TRW5ITVJ?
NCI-H82 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMESzNFch|ryP M3LjZ3NCVkeHUh?=
LC4-1 NGDEWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMESzOVEh|ryP M2rCWHNCVkeHUh?=
HDLM-2 M3[0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rhN2lEPTB;MD6wOFM6OiEQvF2= NFLrc2dUSU6JRWK=
MMAC-SF MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWewWHdiUUN3ME2wMlA1PTN2IN88US=> NEHYb25USU6JRWK=
L-540 NVfzd|h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDjeIVyUUN3ME2wMlA1PjN7IN88US=> NH;3TJdUSU6JRWK=
MZ2-MEL MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMES3OFIh|ryP NXrCUJAyW0GQR1XS
LU-134-A M4HxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHYTWM2OD1yLkC0O|c{KM7:TR?= NHjvRoFUSU6JRWK=
UACC-257 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3oTWM2OD1yLkC0PFQ6KM7:TR?= MlmzV2FPT0WU
NCI-H1581 NUW3WWppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17BbmlEPTB;MD6wOFk2OyEQvF2= M1G1ZnNCVkeHUh?=
NB17 M4q2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMES5O|kh|ryP NHfMNG1USU6JRWK=
SBC-1 NF;IN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTRN2RRUUN3ME2wMlA2ODR{IN88US=> NUG0R3pyW0GQR1XS
TALL-1 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTuTWM2OD1yLkC1NFQ2KM7:TR?= M2i2eXNCVkeHUh?=
NCI-H1304 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnsdVJKSzVyPUCuNFUzODhizszN NWXUZ5diW0GQR1XS
NEC8 NW[4[mNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;SNVBKSzVyPUCuNFUzQDZizszN NUTjOWxKW0GQR1XS
CAL-148 M1q4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfEc|RKSzVyPUCuNFU1OzlizszN MlzVV2FPT0WU
CGTH-W-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS5TWM2OD1yLkC1OFQ6KM7:TR?= M3nDSnNCVkeHUh?=
NCI-H889 M{fpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDvfpdFUUN3ME2wMlA2PTl{IN88US=> Mn\kV2FPT0WU
GR-ST M4HpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPmTWM2OD1yLkC1OlIyKM7:TR?= Mn30V2FPT0WU
KARPAS-422 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;SNGhKSzVyPUCuNFU3PSEQvF2= MmfhV2FPT0WU
RPMI-8866 M1PXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H4c2lEPTB;MD6wOVcyOiEQvF2= MVTTRW5ITVJ?
SCLC-21H M1y4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEW4PFQh|ryP NYTYZYtjW0GQR1XS
COR-L88 NIT6ZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\2enF3UUN3ME2wMlA2QTJ5IN88US=> NY\vU491W0GQR1XS
LU-139 M4\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEW5PFYh|ryP MmiwV2FPT0WU
SF126 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwME[xN|Mh|ryP NFjCNpdUSU6JRWK=
NCI-H1882 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTUOodKSzVyPUCuNFY1OjRizszN NYX4dZhsW0GQR1XS
EW-24 NHT4Z2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:wPGlEPTB;MD6wOlQ5OyEQvF2= MVHTRW5ITVJ?
CP67-MEL NX7NUm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ucGlEPTB;MD6wOlgyKM7:TR?= MU\TRW5ITVJ?
DG-75 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwME[4PVkh|ryP NXLGUFBlW0GQR1XS
LOXIMVI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vRdWlEPTB;MD6wO|AzQCEQvF2= M2q1eHNCVkeHUh?=
HH MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTGTWM2OD1yLkC3NVU4KM7:TR?= NWTNSI97W0GQR1XS
K5 NFnuPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;RboNKSzVyPUCuNFczOjZizszN MY\TRW5ITVJ?
EC-GI-10 NUH6[Y1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEeyOVch|ryP NX30U|FvW0GQR1XS
SK-N-DZ MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfQSIx5UUN3ME2wMlA4OzB5IN88US=> MWHTRW5ITVJ?
A3-KAW NHvEPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnpcI83UUN3ME2wMlA4OzVzIN88US=> NIfoS2VUSU6JRWK=
MLMA NUniSHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RTWM2OD1yLkC3OFY2KM7:TR?= M4DEZXNCVkeHUh?=
LB996-RCC M2fNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHITWM2OD1yLkC3O|A4KM7:TR?= NVvGXml4W0GQR1XS
OS-RC-2 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDOS2tKSzVyPUCuNFc4PDhizszN MX\TRW5ITVJ?
CTB-1 M1O1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojpTWM2OD1yLkC3PFEh|ryP MlPwV2FPT0WU
IST-MES1 NUnVcWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjoN3M5UUN3ME2wMlA4QTF{IN88US=> MXfTRW5ITVJ?
LS-1034 NGjKSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDzTWM2OD1yLkC4NFM2KM7:TR?= NXPYUo1[W0GQR1XS
HT NF\LS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m3OmlEPTB;MD6wPFA5PiEQvF2= Mli5V2FPT0WU
NCI-H2141 M3nCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEixJO69VQ>? MUjTRW5ITVJ?
LB2518-MEL NVvjXY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnjblJKSzVyPUCuNFgyPDFizszN Ml;6V2FPT0WU
GI-ME-N MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSzOGpKSzVyPUCuNFg1PTJizszN M2P0bXNCVkeHUh?=
TGW M1W1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDETWM2OD1yLkC4OlA4KM7:TR?= Ml\UV2FPT0WU
SK-NEP-1 NYPS[ndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37BeWlEPTB;MD6wPFY1OSEQvF2= NUL4O|I6W0GQR1XS
NOMO-1 NITmRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DCN2lEPTB;MD6wPVI4PSEQvF2= M2n1bHNCVkeHUh?=
ES6 NH;3WZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vtRWlEPTB;MD6wPVU5QSEQvF2= MYHTRW5ITVJ?
NCI-H209 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LZOGlEPTB;MD6wPVc5PiEQvF2= MmDyV2FPT0WU
GAK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUCxOkDPxE1? M1e3bHNCVkeHUh?=
BC-1 NVr1N4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfvTWM2OD1yLkGwN|YyKM7:TR?= MkPvV2FPT0WU
KLE NH3FRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTNfHJKSzVyPUCuNVA1PDNizszN Mn;BV2FPT0WU
EW-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fVdWlEPTB;MD6xNFk5KM7:TR?= NH7xTHlUSU6JRWK=
NKM-1 NUjzbG5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\rTWM2OD1yLkGxNUDPxE1? MVHTRW5ITVJ?
D-336MG NWXTbIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0eGlEPTB;MD6xNVI1PCEQvF2= MojRV2FPT0WU
NB69 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyTWM2OD1yLkGxN|AyKM7:TR?= M1zGe3NCVkeHUh?=
D-263MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\wfGlEPTB;MD6xNVcyOiEQvF2= NFfrUnRUSU6JRWK=
KP-N-YS MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\u[YhEUUN3ME2wMlEzOjlzIN88US=> MlnCV2FPT0WU
NCI-H1155 M3;IbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXYTWM2OD1yLkGyOVU5KM7:TR?= MXHTRW5ITVJ?
BOKU MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pk[mlEPTB;MD6xNlU4QSEQvF2= MVXTRW5ITVJ?
LAMA-84 NFf0e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMUK5PUDPxE1? M2\oVXNCVkeHUh?=
Raji MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUOxNVch|ryP NV\rO5ExW0GQR1XS
LU-65 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLLSYNKSzVyPUCuNVM{ODdizszN MYjTRW5ITVJ?
NCI-H187 M3O1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLFN3JRUUN3ME2wMlE{QTJ2IN88US=> NYP0W2dSW0GQR1XS
GCIY NEXocIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUS5NFEh|ryP Mny0V2FPT0WU
NCI-H2107 M{DRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWPXJpUUN3ME2wMlE2ODhizszN NFH5bYVUSU6JRWK=
NCI-H1522 M4XzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPPTWM2OD1yLkG1NlY3KM7:TR?= NGKzfXRUSU6JRWK=
NB6 M4\VSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV64OGFNUUN3ME2wMlE2PjJ|IN88US=> MUfTRW5ITVJ?
EM-2 NHLLd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qxTGlEPTB;MD6xOVcxPiEQvF2= NVjIfGNJW0GQR1XS
HCC2218 M4Pkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z1V2lEPTB;MD6xOVk5KM7:TR?= NGq3XmNUSU6JRWK=
NCI-H748 NYPKZ25QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fMOGlEPTB;MD6xOlM4PiEQvF2= MmrzV2FPT0WU
MS-1 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqTWM2OD1yLkG2OVM4KM7:TR?= MkLDV2FPT0WU
NB5 M{jpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzrdFhKSzVyPUCuNVY2QTdizszN NInteZRUSU6JRWK=
OMC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjvU3hKSzVyPUCuNVY3QDhizszN MlHrV2FPT0WU
NCI-H345 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7nO2txUUN3ME2wMlE3QTJ6IN88US=> MXHTRW5ITVJ?
L-428 M1jMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1yLkG2PVQ2KM7:TR?= NV;NTppSW0GQR1XS
SCH MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTYTWM2OD1yLkG4Olg2KM7:TR?= M1ztbXNCVkeHUh?=
NCI-H1417 NYe0VIQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zCeWlEPTB;MD6xPVIzPyEQvF2= MXHTRW5ITVJ?
COLO-320-HSR NVXXd4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO3TWM2OD1yLkG5OVMzKM7:TR?= NEL4R3RUSU6JRWK=
BT-474 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkemxKSzVyPUCuNlA5QTJizszN MXrTRW5ITVJ?
GDM-1 M1XkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHK[lVWUUN3ME2wMlIyQTdzIN88US=> M{jD[HNCVkeHUh?=
NCI-H2196 NWH4eldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjkU2xKSzVyPUCuNlIzOzVizszN MYHTRW5ITVJ?
KP-N-RT-BM-1 M1\GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jFdGlEPTB;MD6yNlM1QSEQvF2= NVrkNnRzW0GQR1XS
KNS-81-FD M{DYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMTWlEPTB;MD6yNlk2QCEQvF2= NHK5XJRUSU6JRWK=
COLO-668 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\HTWM2OD1yLkKzOlc2KM7:TR?= M1K1VnNCVkeHUh?=
C2BBe1 M2fLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ESolKSzVyPUCuNlY4PDdizszN NGjPRWdUSU6JRWK=
Ramos-2G6-4C10 NW\GUHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jIU2lEPTB;MD6yOlk2PCEQvF2= NXOyepdxW0GQR1XS
CAS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0V2lEPTB;MD6yO|A6PiEQvF2= NYjEPHVVW0GQR1XS
GOTO NYPhZZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPQTWM2OD1yLkK3PFk1KM7:TR?= M{TFPHNCVkeHUh?=
LP-1 NWfYUoZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly4TWM2OD1yLkK4NFU4KM7:TR?= MYHTRW5ITVJ?
NCI-SNU-1 NVHEcYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17JbGlEPTB;MD6yPVQzOiEQvF2= NYfVVpVtW0GQR1XS
EB-3 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPxfJhKSzVyPUCuNlk6PzlizszN Mly5V2FPT0WU
MHH-NB-11 NVfSepR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[zOmlEPTB;MD6zNFQxOiEQvF2= NVLKTmJJW0GQR1XS
SK-N-FI M3Hibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfiNpRHUUN3ME2wMlMyPjl{IN88US=> NUiyVJNzW0GQR1XS
HCC2157 NEPSc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iwXGlEPTB;MD6zN|kyOyEQvF2= MUDTRW5ITVJ?
SIMA NYjLbYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwM{S1PFEh|ryP NIX0[WJUSU6JRWK=
MDA-MB-134-VI Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{[5Nlgh|ryP NHXWS5lUSU6JRWK=
NCI-H1694 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TYVGlEPTB;MD6zO{DPxE1? M4S0XXNCVkeHUh?=
EHEB MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfJTWM2OD1yLkO5NFg2KM7:TR?= MV\TRW5ITVJ?
U-266 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5PGV{UUN3ME2wMlM6QDR4IN88US=> NWjicHdnW0GQR1XS
LC-1F M{nF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfI[lVKSzVyPUCuOFM4PjVizszN NF3SZWVUSU6JRWK=
SHP-77 NGLQdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPZdoJKSzVyPUCuOFc5PTVizszN NXjRRWJTW0GQR1XS
LS-513 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmxUHZKSzVyPUCuOFk{ODdizszN M{OzWXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ:

[1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ

Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験:

[4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 3年-20℃
2年-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

    Answer: S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine sulfateは一種の、チューブと結合することを通じて、マイクロチューブ重合を抑制する阻害剤で、無細胞試験でこのIC50値が32μMです。

  • Nocodazole

    Nocodazoleは一種のマイクロチューブ重合で、迅速可逆的な阻害剤で、無細胞試験でAbl、Abl(E255K)とAbl(T315I)を抑制する時のIC50値が0.21μM、0.53μMと0.64μMにそれぞれ分かれることです。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ